AptarGroup Q3 2025: adj. EPS $1.62 (+4% YoY); pharma injectables surge 18%; Q4 adj. EPS guidance $1.20-$1.28

APTARGROUP, INC.

2025-Q3 EPS reported $4.75 vs consensus $1.58 ▲ beat (+200.1%)

Reported sales $961M (+6% YoY); core sales +1%. Reported EPS $1.92 (+30%); adjusted EPS $1.62 (+4%).
Pharma injectables sales surged 18% driven by GLP-1 components; Pharma core sales +2%.
Beauty core sales flat; Closures core sales -1% due to lower tooling and resin pass-throughs.
Q4 adjusted EPS guidance $1.20-$1.28; returned $70M to shareholders in Q3 via repurchases and dividends.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.